汇宇制药依托泊苷注射液、氟尿嘧啶注射液获得美国FDA批准

Core Viewpoint - Huyou Pharmaceutical has received approval from the U.S. FDA for its new drug applications for Etoposide Injection and Fluorouracil Injection, allowing the company to produce and sell these products in the U.S. market [1] Group 1 - The approval from the U.S. FDA signifies that the company is now qualified to sell products in the U.S. market [1] - This development is expected to help the company expand its sales in the U.S. market and strengthen its product supply chain [1] - The approval also enriches the company's product portfolio and lays a solid foundation for sustainable development in international markets [1]